URAC Rare Disease Pharmacy Certification vs. Specialty Pharmacy Accreditation — Which Credential Does Your Pharmacy Need?
Last updated: April 2026
Specialty pharmacies serving rare and orphan disease patient populations have more than one quality credential available — and the choice between them is consequential. URAC Rare Disease Pharmacy Center of Excellence Certification, URAC Specialty Pharmacy Accreditation, and ACHC specialty pharmacy programs each address different market requirements and serve different strategic purposes. This comparison explains what each credential is, how they relate to each other, and how to determine which path your pharmacy needs.
The Specialty Pharmacy Accreditation Landscape
The specialty pharmacy quality credential market has two primary bodies: URAC and ACHC (Accreditation Commission for Health Care). Each offers specialty pharmacy accreditation programs. Only URAC offers a rare disease-specific designation — the Rare Disease Pharmacy Center of Excellence Certification — making URAC the only relevant path for pharmacies whose primary objective is demonstrating elite rare disease patient management capabilities to manufacturers and payers.
Understanding how these programs relate to each other is the starting point for any accreditation strategy conversation.
The URAC Specialty Pharmacy Program Structure
URAC offers two pharmacy quality programs relevant to rare disease:
- URAC Specialty Pharmacy Accreditation — a standalone three-year credential covering nine operational modules. This is the foundational credential required before pursuing Rare Disease Certification.
- URAC Rare Disease Pharmacy Center of Excellence Certification — a specialized certification layered on top of Specialty Pharmacy Accreditation, adding five standards specific to rare and orphan disease patient management. Approximately 23 pharmacies nationwide hold it.
These are not alternative paths. Rare Disease Certification requires Specialty Pharmacy Accreditation. The question is not which one to pursue — it is whether to pursue Specialty Pharmacy Accreditation alone or Specialty Pharmacy Accreditation plus Rare Disease Certification.
URAC Rare Disease Certification vs. URAC Specialty Pharmacy Accreditation
| Dimension | URAC Specialty Pharmacy Accreditation | URAC Rare Disease Pharmacy Center of Excellence Certification |
|---|---|---|
| Program type | Standalone accreditation | Certification overlay (requires Specialty Pharmacy Accreditation as prerequisite) |
| Standards covered | 9 modules: Risk Management, Operations and Infrastructure, Performance Monitoring and Improvement, Consumer Protection and Empowerment, Pharmacy Operations, Medication Distribution, Patient Service and Communication, Patient Management, Reporting Performance Measures | All 9 Specialty Pharmacy modules PLUS 5 additional rare disease standards: rare disease-specific assessment, disease-specific education, multidisciplinary collaboration, rare disease analytics, rare disease CQI |
| Eligibility requirement | Dispenses specialty medications and provides patient management services | Holds or is actively seeking URAC Specialty Pharmacy Accreditation AND actively dispenses at least one rare or orphan medication |
| Drug focus | All specialty medications | Rare and orphan disease medications (Orphan Drug Act designees) |
| Number of holders (approx.) | Hundreds of specialty pharmacies nationwide | Approximately 23 specialty pharmacies nationwide |
| Primary market signal | Baseline quality credential recognized by payers, health plans, and health systems | Elite rare disease care capability signal recognized by rare disease manufacturers and payers |
| Manufacturer network access | Required by many manufacturers for general specialty drug network access | Primary credential used by rare disease manufacturers evaluating limited-distribution pharmacy partners |
| Patient management standard | Specialty patient management across the full specialty drug portfolio | Disease-specific patient assessment tailored to each rare condition dispensed |
| Education requirements | Patient service and communication standards applicable to all specialty conditions | Disease-specific education programs for patients, caregivers, providers, and payers — one program per rare disease, not a general program |
| Care team requirements | Qualified pharmacy staff providing patient management services | Documented multidisciplinary team collaboration with evidence of actual cross-discipline interaction events |
| Analytics requirements | Performance measure reporting across required specialty pharmacy metrics | Population-level data collection and analytics tracking rare disease patient outcomes specifically |
| CQI requirements | Performance monitoring and improvement program across general specialty pharmacy operations | CQI program evaluated specifically against rare disease performance measures with documented improvement activity |
| Developed with | Pharmacy industry stakeholders | Pharmacy industry stakeholders plus NORD — National Organization for Rare Disorders |
| Survey method | Document review, policy review, patient file audit across 9 modules | Same as Specialty Pharmacy Accreditation plus additional review of the 5 rare disease standards |
URAC vs. ACHC for Rare Disease Pharmacy
ACHC (Accreditation Commission for Health Care) is URAC's primary competitor in specialty pharmacy accreditation. Both offer specialty pharmacy accreditation programs. The comparison matters when a pharmacy is choosing its foundational specialty pharmacy credential — because that choice determines whether Rare Disease Certification is even available.
| Dimension | URAC Specialty Pharmacy + Rare Disease Certification | ACHC Specialty Pharmacy Accreditation |
|---|---|---|
| Rare disease-specific designation | Yes — Rare Disease Pharmacy Center of Excellence Certification available as overlay | No equivalent rare disease-specific designation |
| Limited-distribution drug positioning | URAC Rare Disease Certification is the recognized credential for rare disease manufacturer partnerships | ACHC accreditation may satisfy general specialty manufacturer requirements but does not carry rare disease-specific recognition |
| Patient management standard depth | 9 modules at accreditation level, plus 5 rare disease-specific standards at certification level | Specialty pharmacy standards across core operational domains |
| NORD collaboration | Rare Disease standards developed with NORD input | No equivalent patient advocacy organization collaboration on rare disease standards |
| Market recognition — rare disease manufacturers | URAC Rare Disease Certification directly recognized by rare disease drug manufacturers in network selection | ACHC accreditation recognized for general specialty pharmacy network qualification |
| Payer and health plan recognition | Recognized by most major health plans; state mandates vary by accrediting body requirements | Recognized by most major health plans; state mandates vary by accrediting body requirements |
| Best for | Pharmacies whose strategic priority is rare disease drug access, manufacturer network inclusion, and elite rare disease patient management positioning | Pharmacies whose primary payer and health system contracting relationships specifically require ACHC recognition |
The Decision Rule
If your pharmacy's strategic objective includes rare disease drug access and manufacturer limited-distribution network positioning, URAC is the correct foundational accrediting body. ACHC does not offer a rare disease-specific designation, and choosing ACHC as your foundational accreditation forecloses the Rare Disease Certification pathway.
If your existing health plan and payer contracts require ACHC specifically, ACHC may be the necessary baseline. Some pharmacies hold both URAC and ACHC accreditation to satisfy different contract populations. IHS evaluates your specific contracting relationships in the discovery session and recommends the appropriate path.
Which Path Is Right for Your Pharmacy?
Pursue URAC Specialty Pharmacy Accreditation Only If:
- Your pharmacy dispenses specialty medications but has limited rare disease drug portfolio exposure
- Your primary market positioning goal is payer and health plan network access, not rare disease manufacturer partnerships
- You are building toward Rare Disease Certification but are not yet actively dispensing orphan medications
- Your organization is establishing foundational quality credentials before pursuing advanced designation
Pursue URAC Rare Disease Pharmacy Center of Excellence Certification If:
- Your pharmacy actively dispenses one or more rare or orphan medications — you are already eligible
- You are pursuing or planning to pursue limited-distribution drug contracts with rare disease manufacturers
- Your pharmacy is competing for rare disease patient volumes against large national specialty pharmacy operators
- You hold URAC Specialty Pharmacy Accreditation and want to differentiate on quality in the rare disease market
- Your clinical team already operates with multidisciplinary care coordination for rare disease patients — the certification documents what you are already doing
Pursue Both URAC and ACHC If:
- Your health plan and payer contracts require ACHC for general specialty network access
- Your manufacturer relationships require URAC for rare disease drug access
- Your pharmacy is large enough to absorb the operational and consulting overhead of dual accreditation
- Competitive differentiation in both general specialty and rare disease markets is a strategic priority
Common Comparison Questions
Does holding URAC Specialty Pharmacy Accreditation automatically qualify a pharmacy for Rare Disease Certification?
No. Holding Specialty Pharmacy Accreditation satisfies the prerequisite accreditation requirement, but the five Rare Disease standards must be separately prepared, documented, and surveyed. Many pharmacies hold Specialty Pharmacy Accreditation for years before pursuing Rare Disease Certification — and discover that their existing patient management infrastructure does not satisfy the rare disease-specific standards without targeted remediation. The accreditation gets you to the starting line for Rare Disease Certification; it does not carry you across it.
How does URAC Rare Disease Certification compare to JCAHO specialty pharmacy programs?
The Joint Commission (JCAHO) offers healthcare organization accreditation programs that touch pharmacy operations within larger health system contexts but does not offer a specialty pharmacy-specific or rare disease pharmacy-specific certification equivalent to URAC's programs. Health systems with Joint Commission hospital accreditation may operate specialty pharmacy services under that umbrella, but for standalone specialty pharmacies and rare disease drug access purposes, URAC and ACHC are the relevant comparators.
Is URAC Rare Disease Pharmacy Certification recognized by all rare disease manufacturers?
No individual accrediting body's credential is universally recognized or required by every manufacturer in every therapeutic category. Manufacturer network access decisions are made by each manufacturer independently, and criteria vary. URAC Rare Disease Pharmacy Center of Excellence Certification is the most widely recognized rare disease-specific quality credential in the specialty pharmacy space and is a factor in many manufacturer network selection processes. It does not guarantee access to any specific network — it positions your pharmacy as a demonstrably qualified candidate.
My pharmacy already holds ACHC accreditation. Can we also pursue URAC Rare Disease Certification?
URAC Rare Disease Certification requires URAC Specialty Pharmacy Accreditation as the prerequisite — not ACHC accreditation. A pharmacy holding ACHC accreditation but not URAC Specialty Pharmacy Accreditation would need to pursue URAC Specialty Pharmacy Accreditation first, then layer Rare Disease Certification on top. This means a dual accreditation path (ACHC + URAC Specialty Pharmacy + URAC Rare Disease Certification). IHS evaluates whether that path makes strategic and operational sense for your specific organization before recommending it.
IHS Perspective: What the Numbers Tell You
Approximately 23 specialty pharmacies hold URAC Rare Disease Pharmacy Center of Excellence Certification. There are more than 30,000 pharmacies in the United States, of which several thousand operate as specialty pharmacies. The certification is held by fewer than one-tenth of one percent of all pharmacies in the country.
That selectivity is not accidental. The certification is designed to identify pharmacies operating at a genuinely different standard of rare disease care — with the clinical infrastructure, multidisciplinary team structure, disease-specific programming, and outcomes analytics to serve patients who have few treatment options and no margin for pharmacy failures. The small number of holders is a feature of the program's design, not a limitation of its adoption.
For pharmacies that meet the eligibility criteria and have the operational foundation to pursue it, Rare Disease Certification is the clearest market differentiator available in the specialty pharmacy accreditation landscape. Thomas G. Goddard, JD, PhD, former Chief Operating Officer and General Counsel of URAC, leads IHS URAC engagements with firsthand knowledge of how these programs were designed and how they are evaluated.
Schedule a Free Discovery Session
IHS offers a complimentary discovery session to help your pharmacy determine which accreditation path — URAC Specialty Pharmacy Accreditation, URAC Rare Disease Pharmacy Center of Excellence Certification, ACHC, or a combination — is appropriate given your drug portfolio, existing accreditation posture, and market objectives. Bring your drug list, your current accreditation status, and your contracting priorities.